# Perioperative Versus Postoperative CapOX Chemotherapy for Locally Advanced Colon Cancer

Source: https://onco.cc/trials/nct03125980/  
OnCo record `nct03125980` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of capecitabine in colorectal cancer, run by Fudan University, now recruiting.

## Summary

Perioperative Versus Postoperative CapOX Chemotherapy for Locally Advanced Colon Cancer is a phase 3, randomised interventional study registered as NCT03125980 by Fudan University, with a registry enrolment figure of 1370 participants, started 2017-05 and due to reach its primary completion in 2022-05. Interventions recorded: capecitabine plus oxaliplatin before and after surgery; capecitabine plus oxaliplatin after surgery. Conditions listed: Locally Advanced Colon Cancer. Primary outcome: 3-year disease free survival. Colorectal eligibility wording from the registry: "* No previous systemic chemotherapy for treating colon cancer;". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT03125980
- Phase: 3
- Setting: Perioperative CapeOX Chemotherapy Versus Postoperative Chemotherapy for Locally Advanced Resectable Colon Cancer: An Open Label Randomized Controlled Phase III Trial
- Sponsor: Fudan University
- Enrolled: 1370

## Sources

- ClinicalTrials.gov NCT03125980: https://clinicaltrials.gov/study/NCT03125980

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct03125980.json